Virus
AssigneeiosBio Ltd
InventorJeffrey Drew
Life of this patent
Estimating the term…
Abstract
The invention is in the field of delivery of transgenes to target cells using viral vectors, particularly in the field of gene therapy. Compositions have been identified which allow for oral administration of viral particles, particularly adenoviral particles.
Claims12
A tablet or capsule for oral administration to a patient comprising adenoviral particles carrying a transgene, wherein the transgene encodes one or more antigens, and wherein the tablet or capsule is prepared by formulating the adenoviral particles comprising the transgene into a liquid composition which comprises:
- (a) sucrose at a concentration of 0.05 to 1 M;
- (b) N,N-dimethylglycine or a physiologically acceptable salt or ester thereof at a concentration of 0.07 to 1 M;
- and
- (c) dimethylsulfone at a concentration of 0.07 to 1 M;
- drying the liquid composition, and packaging the dried composition into the tablet or capsule, wherein the tablet or capsule is coated with an enteric coating.
A method of delivering a transgene(s) which encodes one or more antigens to target cells in a patient, said method comprising oral administration of a tablet or capsule comprising adenoviral particles which carry the transgene to the patient, wherein the tablet or capsule is prepared by formulating the adenoviral particles comprising the transgene into a liquid composition which comprises:
- (a) sucrose at a concentration of 0.05 to 1 M;
- (b) N,N-dimethylglycine or a physiologically acceptable salt or ester thereof at a concentration of 0.07 to 1 M;
- and
- (c) dimethylsulfone at a concentration of 0.07 to 1 M;
- drying the liquid composition, and packaging the dried composition into the tablet or capsule, wherein the tablet or capsule is enterically coated.
A method of preparing adenoviral particles carrying a transgene which encodes one or more antigens for oral administration to a patient, said method comprising:
- (a) culturing and purifying adenoviral particles carrying the transgene;
- (b) formulating the viral particles in a pharmaceutical liquid composition which comprises
- (i) sucrose at a concentration of 0.05 to 1 M;
- (ii) N,N-dimethylglycine or a physiologically acceptable salt or ester thereof at a concentration of 0.07 to 1 M;
- and
- (iii) dimethylsulfone at a concentration of 0.07 to 1 M;
- (c) drying the liquid composition;
- and
- (d) packaging the dried composition into tablets or capsules for oral administration to the patient, wherein the tablets or capsules are coated with an enteric coating.
Dependencies are inferred from the claim text.